Latest Headlines

  1. Andelyn Biosciences To Implement Curator® Platform To Develop And Manufacture Gene Therapy AAV9-GM2 For Queen's University To Treat GM2 Gangliosidoses 9/21/2026

    Andelyn Biosciences, Inc., a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy candidate for the treatment of GM2 gangliosidoses, such as Tay-Sachs and Sandhoff diseases.

  2. Andelyn Biosciences And Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following The FDA's Approval Of Ultragenyx's Fayuvi™ For The Treatment Of Sanfilippo Syndrome Type A (MPS IIIA) 9/21/2026

    Andelyn Biosciences (“Andelyn”), a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (“CDMO”), today announced that it is now manufacturing Fayuvi™ (rebisufligene etisparvovec-hopf), an FDA-approved gene therapy, for commercial supply at its Columbus, Ohio facility. 

  3. Emulate Enters Final Stage Of FDA ISTAND Program For Human Liver-Chip With Submission Of Qualification Package Covering Both Zoë® And AVA™ Organ-Chip Platforms 9/18/2026
  4. 3PBIOVIAN Appoints Ponchi Kantt-Neaz As Global Executive Business Director, Marking A Milestone In Its oCommercial Strategy 9/16/2026

    3PBIOVIAN has appointed Ponchi Kantt-Neaz as Global Executive Business Director, marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.

  5. Andelyn Biosciences To Scale Manufacturing For Genprex's Diabetes Gene Therapy Program 9/1/2026
  6. AST Names Industry Veteran Jon Lenihan As Chief Commercial Officer 8/31/2026
  7. AES Cleanroom Technology Panels Earn FM 4882 Approval, Addressing The Cleanroom Risk That Fire Ratings Miss 8/27/2026
  8. 4th Cell Therapy for Autoimmune Disease Summit 8/27/2026

    As cell therapy for autoimmune disease transitions from breakthrough clinical case studies to broad clinical validation, developers are racing to overcome challenges around safety, scalability, durability of response, and patient access while advancing the next generation of immune reset therapies.

  9. Avance Clinical Appoints Inaugural Chief Commercial Officer, Reinforcing Global Growth Strategy 8/25/2026

    Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing international biotechs, today announced the appointment of Tim Schuckman as its first Chief Commercial Officer (CCO). Schuckman joined the company on Monday 17 August in a newly created executive role that reflects Avance Clinical’s continued growth, deeper client partnerships, and expanding presence across North America, Asia, and Europe.

  10. Landmark Bio And Syngoi Technologies To Operate As Artis BioSolutions, An End-To-End Gene-To-GMP Platform For Genetic Medicines 7/29/2026

    Artis BioSolutions, an advanced therapies company built to streamline the discovery, development, and production of genetic medicines, today announced that both Landmark Bio, its Watertown, Massachusetts-based development and GMP manufacturing operation, and Syngoi, its Bilbao, Spain-based enzymatic synthetic DNA business, will now operate under the Artis BioSolutions name.